Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04895982 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 21, 2021
Last Update Posted : February 14, 2023
|
Sponsor:
BioNTech SE
Collaborator:
Pfizer
Information provided by (Responsible Party):
BioNTech SE
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | August 1, 2023 |
| Estimated Study Completion Date : | August 1, 2023 |